Targeted exome sequencing identified a biallelic PALB2 mutation, a CHEK2 mutation and amplification of MYC. An ex vivo drug screen was performed to test sensitivity of the patient derived tumor cells to 165 anti-cancer drugs [15–17]. This evidence concerns the gene PALB2 and neoplasm.